1. Home
  2. ASA vs CRVS Comparison

ASA vs CRVS Comparison

Compare ASA & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ASA

ASA Gold and Precious Metals Limited

HOLD

Current Price

$67.25

Market Cap

1.2B

Sector

Industrials

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$18.15

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASA
CRVS
Founded
1958
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
2003
2016

Fundamental Metrics

Financial Performance
Metric
ASA
CRVS
Price
$67.25
$18.15
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$30.17
AVG Volume (30 Days)
46.6K
966.0K
Earning Date
06-01-2026
05-07-2026
Dividend Yield
0.09%
N/A
EPS Growth
N/A
48.04
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.96
N/A
Revenue Growth
N/A
N/A
52 Week Low
$28.67
$3.17
52 Week High
$83.20
$26.95

Technical Indicators

Market Signals
Indicator
ASA
CRVS
Relative Strength Index (RSI) 52.72 64.18
Support Level $65.80 $16.15
Resistance Level $73.60 $18.73
Average True Range (ATR) 2.36 1.02
MACD 0.55 0.39
Stochastic Oscillator 59.28 70.07

Price Performance

Historical Comparison
ASA
CRVS

About ASA ASA Gold and Precious Metals Limited

ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: